# Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

> **NCT05097716** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Ritlecitinib
- **DRUG:** Tolbutamide

## Key facts

- **NCT ID:** NCT05097716
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-02
- **Primary completion:** 2022-01-10
- **Final completion:** 2022-01-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097716, "Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05097716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*